Info

BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. Our technology platform uniquely positions us to rapidly and cost-effectively discover new high-value biomarkers over a broad range of therapeutic categories that promise to be highly correlated to clinical outcomes. We have built a broad product pipeline that focuses on cardiovascular disease, cancer and CNS disorders through academic collaborations and initiatives with major pharmaceutical companies, the U.S Food and Drug Administration, or FDA and other healthcare organizations. We discover biomarkers employing our proprietary, versatile, scalable technology platform that enables us to identify new biomarkers by integrating, and automating measurement, analysis, characterizations and interpretations of proteins and small non-protein biological molecules, or metabolites, collected from bodily fluids. Through our biomarker discovery and product development programs we develop molecular diagnostic tests that are intended to provide information to physicians that will greatly improve patient treatment decisions. Our tests are designed to predict a patient's response to drug therapy, determine the potential toxicity of therapeutic agents to patients, identify patients who have or are likely to develop a specific disease, predict a patient's prognosis once a disease has been diagnosed and monitor a patient's disease progression or drug response.